Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biodesix, Inc.
  6. News
  7. Summary
    BDSX   US09075X1081

BIODESIX, INC.

(BDSX)
  Report
Delayed Nasdaq  -  04:00 2022-12-06 pm EST
1.340 USD   -6.29%
12/01Top Premarket Decliners
MT
11/22Insider Buy: Biodesix
MT
11/22Insider Buy: Biodesix
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Biodesix to Participate in Two Upcoming Investor Conferences in September

09/06/2022 | 06:01am EST

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences:

Morgan Stanley 20th Annual Global Healthcare Conference
Date: Tuesday, September 13, 2022 at 9:10 a.m. ET
Format: Fireside Chat and 1x1 meetings
Location: Sheraton Hotel, New York, NY
Details: The fireside chat will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at www.biodesix.com.

H.C. Wainwright 24th Annual Global Investment Conference
Dates: September 12-14, 2022
Format: 1x1 meetings
Location: Lotte New York Palace Hotel, New York, NY

About Biodesix

Biodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer eight non-invasive tests for patients with lung diseases. The blood based Nodify Lung® nodule risk assessment testing strategy, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood based IQLung™ strategy for lung cancer patients integrates the GeneStrat® ddPCR™ test, the GeneStrat NGS™ test and the VeriStrat® test to support treatment decisions across all stages of lung cancer with results in an unprecedented 36-72 hours, expediting time to treatment. Biodesix also leverages the proprietary and advanced Diagnostic Cortex® AI (Artificial Intelligence) platform, to collaborate with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. Biodesix launched the SARS-CoV-2 ddPCR™ test, the Platelia SARS-CoV-2 Total Ab, and the cPass™ SARS-CoV-2 Neutralization Antibody test (cPass™ Neutralization Test Kit, GenScript, Inc,) in response to the global pandemic and virus that impacts the lung and causes COVID-19. For more information about Biodesix, visit biodesix.com.

Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning the impact of the COVID-19 pandemic on Biodesix and its operations, it is possible or assumed future results of operations, including descriptions of its revenues, profitability, outlook, and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. The Company's ability to continue as a going concern could cause actual results to differ materially from those contemplated in this press release and additionally, other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix’s most recent annual report on Form 10-K, filed March 14, 2022 or subsequent quarterly reports on Form 10-Q during 2022, if applicable. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.


ę Business Wire 2022
All news about BIODESIX, INC.
12/01Top Premarket Decliners
MT
11/22Insider Buy: Biodesix
MT
11/22Insider Buy: Biodesix
MT
11/22Insider Buy: Biodesix
MT
11/21Biodesix Inc : Entry into a Material Definitive Agreement, Termination of a Material Defin..
AQ
11/21Biodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Pu..
BU
11/17Biodesix Announces Proposed Public Offering of Common Stock - November 16, 2022
AQ
11/17Biodesix Prices $35.1 Million Common Stock Offering
MT
11/17Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock
BU
11/16Biodesix Announces Proposed Public Offering of Common Stock
BU
More news
Analyst Recommendations on BIODESIX, INC.
More recommendations
Financials (USD)
Sales 2022 39,3 M - -
Net income 2022 -59,2 M - -
Net cash 2022 0,30 M - -
P/E ratio 2022 -0,91x
Yield 2022 -
Capitalization 103 M 103 M -
EV / Sales 2022 2,60x
EV / Sales 2023 0,84x
Nbr of Employees 218
Free-Float 29,1%
Chart BIODESIX, INC.
Duration : Period :
Biodesix, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIODESIX, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,34 $
Average target price 5,00 $
Spread / Average Target 273%
EPS Revisions
Managers and Directors
Scott Hutton President, Chief Executive Officer & Director
Robin Harper Cowie CFO, Secretary, Treasurer & CAO
John Patience Chairman
James R. Jett Co-Chief Medical Officer
Steven C. Springmeyer Co-Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
BIODESIX, INC.-74.67%103
SONIC HEALTHCARE LIMITED-32.34%10 093
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.-36.81%4 702
SYNLAB AG-42.69%3 126
DR. LAL PATHLABS LIMITED-35.02%2 511
DIAGNOSTICOS DA AMÉRICA S.A.-58.39%1 492